Compare XBIT & RSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | RSSS |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.0M | 86.5M |
| IPO Year | 2015 | 2008 |
| Metric | XBIT | RSSS |
|---|---|---|
| Price | $2.41 | $2.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 21.3K | ★ 76.6K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.77 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $28,793,922.00 |
| Revenue This Year | N/A | $1.81 |
| Revenue Next Year | N/A | $5.73 |
| P/E Ratio | ★ N/A | $59.75 |
| Revenue Growth | N/A | ★ 2.77 |
| 52 Week Low | $2.09 | $2.11 |
| 52 Week High | $3.61 | $4.12 |
| Indicator | XBIT | RSSS |
|---|---|---|
| Relative Strength Index (RSI) | 38.96 | 36.49 |
| Support Level | $2.35 | N/A |
| Resistance Level | $2.41 | $2.64 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 4.00 | 20.00 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.